Alterity Therapeutics Limited's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Alterity Therapeutics Limited (ATHE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Alterity Therapeutics Limited vs Its Competitors
- Scale: Alterity Therapeutics Limited ranks #29 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.3% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Alterity Therapeutics Limited's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Alterity Therapeutics Limited | - | - | - | No |
| Competitors combined (16) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ATHE Stock Performance relative to its Competitors
ATHE Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Intra cellular Therapies Inc | 282.9% | Outperformed |
| 2 | Biohaven Ltd | 282.9% | Outperformed |
| 3 | Neurocrine Biosciences Inc | 282.9% | Outperformed |
| 4 | Acadia Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Unicycive Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Alterity Therapeutics Limited's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Alterity Therapeutics Limited's Comment on Competition and Industry Peers
Publicly Traded Peers of Alterity Therapeutics Limited
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Alterity Therapeutics Limited |
15,408.91 | - |
 Neurocrine Biosciences Inc |
17,249.12 | 3,701.70 |
 Intra cellular Therapies Inc |
13,599.88 | 680.85 |
 Crinetics Pharmaceuticals Inc |
8,967.32 | 42.16 |
 Cerevel Therapeutics Holdings Inc |
8,165.22 | 0.00 |
 Acadia Pharmaceuticals Inc |
3,730.58 | 1,202.30 |
| SUBTOTAL | 70,286.00 | 6,563.79 |
Sign in to see all competitors of Alterity Therapeutics Limited.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Alterity Therapeutics Limited versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Alterity Therapeutics Limited's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Neurocrine Biosciences Inc | Reportable 100.00 % |
| Crinetics Pharmaceuticals Inc | Reportable 100.00 % |
| Acadia Pharmaceuticals Inc | Reportable Segment Aggregation Before Other Operating Segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Alterity Therapeutics Limited's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Alterity Therapeutics Limited | 15,409 | - | -715,480 |
| Neurocrine Biosciences Inc | 17,249 | 1,850,850 | 351,250 |
| Intra cellular Therapies Inc | 13,600 | 3,370,554 | -369,683 |
| Crinetics Pharmaceuticals Inc | 8,967 | 70,970 | -844,455 |
| Cerevel Therapeutics Holdings Inc | 8,165 | 0 | -1,771,031 |
| Acadia Pharmaceuticals Inc | 3,731 | 1,506,643 | 453,921 |
| PEERS TOTAL | 54,877 | 1,432,203 | -233,417 |
Sign in to see all peers for Alterity Therapeutics Limited.
Alterity Therapeutics Limited's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Alterity Therapeutics Limited's industry classification, broader than the peer set above. Market cap in millions of $.Alterity Therapeutics Limited ranks #29 of 495 companies by market capitalization in its industry, holding 0.26 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 885, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,232,412 | 20.92 % |
| 2 | Johnson and Johnson | 679,690 | 11.54 % |
| 3 | Beone Medicines Ltd | 623,340 | 10.58 % |
| 4 | Abbvie Inc | 514,617 | 8.74 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 29 | Alterity Therapeutics Limited | 15,409 | 0.26 % |
Market cap and industry share for the rest of Alterity Therapeutics Limited's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Alterity Therapeutics Limited's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 24 | Insmed Inc | 24,580 | -39.09 % |
| 25 | Viatris Inc | 23,254 | 97.73 % |
| 26 | Alnylam Pharmaceuticals Inc | 21,233 | -65.14 % |
| 27 | Jazz Pharmaceuticals Plc | 16,373 | 76.00 % |
| 28 | Ascendis Pharma A | 1,234 | 12.3% |
| 29 | Alterity Therapeutics Limited | 15,409 | -31.18 % |
| 30 | Bridgebio Pharma Inc | 1,234 | 12.3% |
| 31 | Elanco Animal Health Incorporated | 1,234 | 12.3% |
| 32 | Hutchmed china Limited | 1,234 | 12.3% |
| 33 | Summit Therapeutics Inc | 1,234 | 12.3% |
| 34 | Dr Reddy s Laboratories Limited | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Alterity Therapeutics Limited's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Alterity Therapeutics Limited's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | 900.3x | 4.3x | +896.1x |
| Return on Equity | -28.24 % | industry aggregate | -47.08 % |
| Return on Invested Capital | -35.62 % | -9.82 % (avg) | -25.80 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Alterity Therapeutics Limited's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Alterity Therapeutics Limited falls in the Dog quadrant: relative market share of 0.01x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Alterity Therapeutics Limited's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 885 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Alterity Therapeutics Limited's dedicated Suppliers and Customers pages, not here.
Alterity Therapeutics Limited's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Alterity Therapeutics Limited falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Alterity Therapeutics Limited's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 47.1 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.01x).
Opportunities
- A meaningful share of competitors (73.30 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-32.9% annualized).
Methodology: see Methodology: SWOT Analysis.
Alterity Therapeutics Limited's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Alterity Therapeutics Limited | 9.38 | 12.98 | - |
| Neurocrine Biosciences Inc | 0.57 | 2.51 | - |
| Intra cellular Therapies Inc | 2.40 | 6.78 | - |
| Crinetics Pharmaceuticals Inc | 4.92 | 15.27 | - |
| Cerevel Therapeutics Holdings Inc | 3.33 | 10.31 | 0.91 |
| Acadia Pharmaceuticals Inc | 0.91 | 3.68 | - |
Sign in to see all peers for Alterity Therapeutics Limited.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Alterity Therapeutics Limited's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Alterity Therapeutics Limited | Q2 2025 | - | - |
| Neurocrine Biosciences Inc | Q3 2026 | +41.2 % | -1.4 % |
| Intra cellular Therapies Inc | Q4 2024 | +50.8 % | - |
| Crinetics Pharmaceuticals Inc | Q2 2026 | +2,336.3 % | - |
| Cerevel Therapeutics Holdings Inc | Q1 2024 | - | - |
| Acadia Pharmaceuticals Inc | Q3 2026 | +22.8 % | -25.4 % |
| PEERS TOTAL | +38.1 % | - |
Sign in to see all peers for Alterity Therapeutics Limited.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Alterity Therapeutics Limited's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Alterity Therapeutics Limited | Q2 2025 | - | - |
| Neurocrine Biosciences Inc | Q3 2026 | +104.6 % | -12.1 % |
| Intra cellular Therapies Inc | Q4 2024 | - | - |
| Crinetics Pharmaceuticals Inc | Q2 2026 | - | -83.7 % |
| Cerevel Therapeutics Holdings Inc | Q1 2024 | - | -19.3 % |
| Acadia Pharmaceuticals Inc | Q3 2026 | +62.1 % | +219.6 % |
Sign in to see all peers for Alterity Therapeutics Limited.
Alterity Therapeutics Limited's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Alterity Therapeutics Limited | - | - | - |
| Neurocrine Biosciences Inc | 13.69% | 16.94% | 19.74% |
| Intra cellular Therapies Inc | - | - | - |
| Crinetics Pharmaceuticals Inc | - | - | - |
| Cerevel Therapeutics Holdings Inc | - | - | - |
| Acadia Pharmaceuticals Inc | 21.60% | 26.89% | 28.03% |
Sign in to see all peers for Alterity Therapeutics Limited.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Alterity Therapeutics Limited's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Alterity Therapeutics Limited | - | - |
| Neurocrine Biosciences Inc | 24.24 | 4.66 |
| Intra cellular Therapies Inc | - | 19.97 |
| Crinetics Pharmaceuticals Inc | - | 212.72 |
| Cerevel Therapeutics Holdings Inc | - | - |
| Acadia Pharmaceuticals Inc | 10.03 | 3.10 |
| PEERS AVERAGE | - | 10.71 |
Sign in to see all peers for Alterity Therapeutics Limited.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.